San Francisco startup Framework Therapeutics can be engaged on an oral, once-every day GLP-one drug referred to as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June every time a mid-phase analyze showed average weight loss of about six% and it ideas to get started on another mid-stage trial in the direction of the end of the yr—